Vericel Corporation (NASDAQ:VCEL)’s share price gapped up before the market opened on Wednesday . The stock had previously closed at $3.95, but opened at $4.10. Vericel Corporation shares last traded at $4.15, with a volume of 2,305,629 shares traded.

A number of equities analysts have issued reports on the company. Piper Jaffray Companies restated a “buy” rating and set a $7.00 target price on shares of Vericel Corporation in a report on Thursday, August 10th. BTIG Research set a $6.00 target price on Vericel Corporation and gave the stock a “buy” rating in a report on Wednesday, August 9th.

The stock has a 50-day moving average price of $3.40 and a 200 day moving average price of $2.98. The company’s market cap is $141.14 million.

Vericel Corporation (NASDAQ:VCEL) last issued its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.16. The company had revenue of $16.95 million during the quarter. On average, equities analysts expect that Vericel Corporation will post ($0.63) EPS for the current year.

Large investors have recently modified their holdings of the stock. Stonepine Capital Management LLC boosted its stake in shares of Vericel Corporation by 73.3% in the first quarter. Stonepine Capital Management LLC now owns 3,265,323 shares of the biotechnology company’s stock valued at $9,143,000 after buying an additional 1,381,523 shares during the last quarter. Archon Capital Management LLC bought a new stake in shares of Vericel Corporation during the second quarter valued at $4,412,000. Vanguard Group Inc. boosted its stake in shares of Vericel Corporation by 7.9% in the second quarter. Vanguard Group Inc. now owns 1,212,799 shares of the biotechnology company’s stock valued at $4,002,000 after buying an additional 88,645 shares during the last quarter. First Washington CORP bought a new stake in shares of Vericel Corporation during the second quarter valued at $2,230,000. Finally, Perkins Capital Management Inc. boosted its stake in shares of Vericel Corporation by 12.6% in the second quarter. Perkins Capital Management Inc. now owns 257,600 shares of the biotechnology company’s stock valued at $850,000 after buying an additional 28,850 shares during the last quarter. 33.87% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This report was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://www.dailypolitical.com/2017/09/01/vericel-corporation-vcel-shares-gap-up-to-4-10-2.html.

About Vericel Corporation

Vericel Corporation, formerly Aastrom Biosciences, Inc, is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.